Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed
Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. Caffeine is known to augment radiation or chemotherapeutic drug-induced cell killing. The current study addresses the impact of caffeine on the activity of pemetrexed in mesothelioma...
Saved in:
Published in | Cancer chemotherapy and pharmacology Vol. 61; no. 5; pp. 819 - 827 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer-Verlag
01.04.2008
Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. Caffeine is known to augment radiation or chemotherapeutic drug-induced cell killing. The current study addresses the impact of caffeine on the activity of pemetrexed in mesothelioma cell lines. Caffeine enhanced pemetrexed activity in all four mesothelioma cell lines tested (H2052, H2373, H28 and MSTO-211H). Caffeine sensitized H2052 cells in a dose- and schedule-dependent manner, and was associated with a markedly decreased clonogenic survival. Caffeine sensitization occurred only in cells subjected to pulse, but not continuous, exposure to pemetrexed. Similar pemetrexed sensitization was also observed with the clinically better tolerated caffeine analog, theobromine. Pemetrexed sensitization by caffeine was associated with an increase in pemetrexed-induced phosphorylation of ataxia-telangiectasia-mutated (ATM) and Chk1. These data indicate that caffeine and its analog, theobromine, may be a useful approach to enhance pemetrexed-based chemotherapy. |
---|---|
AbstractList | Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. Caffeine is known to augment radiation or chemotherapeutic drug-induced cell killing. The current study addresses the impact of caffeine on the activity of pemetrexed in mesothelioma cell lines. Caffeine enhanced pemetrexed activity in all four mesothelioma cell lines tested (H2052, H2373, H28 and MSTO-211H). Caffeine sensitized H2052 cells in a dose- and schedule-dependent manner, and was associated with a markedly decreased clonogenic survival. Caffeine sensitization occurred only in cells subjected to pulse, but not continuous, exposure to pemetrexed. Similar pemetrexed sensitization was also observed with the clinically better tolerated caffeine analog, theobromine. Pemetrexed sensitization by caffeine was associated with an increase in pemetrexed-induced phosphorylation of ataxia-telangiectasia-mutated (ATM) and Chk1. These data indicate that caffeine and its analog, theobromine, may be a useful approach to enhance pemetrexed-based chemotherapy. Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. Caffeine is known to augment radiation or chemotherapeutic drug-induced cell killing. The current study addresses the impact of caffeine on the activity of pemetrexed in mesothelioma cell lines. Caffeine enhanced pemetrexed activity in all four mesothelioma cell lines tested (H2052, H2373, H28 and MSTO-211H). Caffeine sensitized H2052 cells in a dose- and schedule-dependent manner, and was associated with a markedly decreased clonogenic survival. Caffeine sensitization occurred only in cells subjected to pulse, but not continuous, exposure to pemetrexed. Similar pemetrexed sensitization was also observed with the clinically better tolerated caffeine analog, theobromine. Pemetrexed sensitization by caffeine was associated with an increase in pemetrexed-induced phosphorylation of ataxia-telangiectasia-mutated (ATM) and Chk1. These data indicate that caffeine and its analog, theobromine, may be a useful approach to enhance pemetrexed-based chemotherapy. [PUBLICATION ABSTRACT] |
Author | Goldman, I. David Zhao, Rongbao Min, Sang Hee |
Author_xml | – sequence: 1 givenname: Sang Hee surname: Min fullname: Min, Sang Hee organization: Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine – sequence: 2 givenname: I. David surname: Goldman fullname: Goldman, I. David organization: Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine – sequence: 3 givenname: Rongbao surname: Zhao fullname: Zhao, Rongbao email: rzhao@aecom.yu.edu organization: Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20144926$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17594092$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kV9LHDEUxUOx1NX2A_hShkJ9m3rzz0xeCmXRWhD6Up9DJnPHjZ1JtslMqfvpzbKLWsGnXLi_c3MO54gchBiQkBMKXyiAOssArIG6jDVIruvNG7KggrMaGsEPyAK4ELVUIA7JUc53ACAo5-_IIVVSC9BsQa6Wtu_RB6xGm35jN9xXGUP2k99grlbzaEM1Yo7TCgcfR1s5HIZqKIJcTbFa44hTwn_YvSdveztk_LB_j8nN5cWv5VV9_fP7j-W369oJrabacYTzDhVlDUdkveJU21YyRYFJ3gjRd5oilYrqlinHG5CyaZVwrVCqt5wfk6-7u-u5HbFzGKZkB7NOvgS4N9F68_8m-JW5jX8NbxrJuC4HTvcHUvwzY57M6PM2lQ0Y52wUFEuMygJ-egHexTmFEs4wyoUuEUSB6A5yKeacsH90QsFsSzK7ksx23JZkNkXz8XmEJ8W-lQJ83gM2Ozv0yQbn8yPHgAqh2Xnh2I7LZRVuMT05fP33B09LrCs |
CODEN | CCPHDZ |
CitedBy_id | crossref_primary_10_1016_j_lungcan_2009_03_016 crossref_primary_10_2298_SARH230325027P crossref_primary_10_1007_s00280_007_0608_3 crossref_primary_10_1080_15376516_2017_1296049 crossref_primary_10_1002_mc_21842 crossref_primary_10_1016_j_ejphar_2011_04_057 crossref_primary_10_1038_sj_bjc_6605501 crossref_primary_10_1007_s10637_014_0114_5 |
Cites_doi | 10.1093/jnci/82.13.1107 10.1007/s00280-005-0036-1 10.1038/sj.onc.1203953 10.1200/JCO.2004.08.163 10.1074/jbc.275.14.10342 10.1200/JCO.2003.11.136 10.1038/sj.onc.1203077 10.1006/excr.1998.4122 10.1074/jbc.M307088200 10.1097/01.coc.0000037143.60502.54 10.1038/nm1096-1140 10.1038/sj.onc.1207168 10.1002/bdd.384 10.1074/jbc.M314191200 10.1093/jnci/81.22.1735 10.1158/0008-5472.CAN-04-2461 10.1016/0090-8258(90)90065-S 10.1016/j.bbrc.2004.01.006 10.1097/00000421-200008000-00022 10.1016/S0960-9822(99)80486-2 10.1096/fj.04-1990fje 10.1158/1078-0432.1294.11.3 10.1038/bjc.1981.98 |
ContentType | Journal Article |
Copyright | Springer-Verlag 2007 2008 INIST-CNRS Springer-Verlag 2008 Springer-Verlag 2007 2007 |
Copyright_xml | – notice: Springer-Verlag 2007 – notice: 2008 INIST-CNRS – notice: Springer-Verlag 2008 – notice: Springer-Verlag 2007 2007 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1007/s00280-007-0539-z |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Public Health Oncogenes and Growth Factors Abstracts ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Public Health MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-0843 |
EndPage | 827 |
ExternalDocumentID | 1582093001 10_1007_s00280_007_0539_z 17594092 20144926 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA082621 – fundername: NCI NIH HHS grantid: CA-82621 – fundername: National Cancer Institute : NCI grantid: R01 CA082621 || CA |
GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z7V Z7X Z82 Z83 Z87 Z8O Z8P Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM H13 IQODW AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c497t-c3e06de71283ee2f7319ab52710253844fd91e15719b27c380558b74cb477fa33 |
IEDL.DBID | BENPR |
ISSN | 0344-5704 |
IngestDate | Tue Sep 17 21:23:09 EDT 2024 Fri Aug 16 07:48:10 EDT 2024 Thu Oct 10 22:55:30 EDT 2024 Thu Sep 12 18:47:10 EDT 2024 Tue Oct 15 23:29:12 EDT 2024 Sun Oct 22 16:08:28 EDT 2023 Sat Dec 16 12:00:13 EST 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Theobromine Mesothelioma Pemetrexed Caffeine Antineoplastic agent Antifolate Human Established cell line Tumor Xanthine derivatives In vitro |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c497t-c3e06de71283ee2f7319ab52710253844fd91e15719b27c380558b74cb477fa33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://europepmc.org/articles/pmc3885239?pdf=render |
PMID | 17594092 |
PQID | 213491284 |
PQPubID | 48447 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3885239 proquest_miscellaneous_70319215 proquest_journals_213491284 crossref_primary_10_1007_s00280_007_0539_z pubmed_primary_17594092 pascalfrancis_primary_20144926 springer_journals_10_1007_s00280_007_0539_z |
PublicationCentury | 2000 |
PublicationDate | 2008-04-01 |
PublicationDateYYYYMMDD | 2008-04-01 |
PublicationDate_xml | – month: 04 year: 2008 text: 2008-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | Cancer chemotherapy and pharmacology |
PublicationTitleAbbrev | Cancer Chemother Pharmacol |
PublicationTitleAlternate | Cancer Chemother Pharmacol |
PublicationYear | 2008 |
Publisher | Springer-Verlag Springer Springer Nature B.V |
Publisher_xml | – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
References | Fingert, Chang, Pardee (CR13) 1986; 46 Vogelzang, Rusthoven, Symanowski, Denham, Kaukel, Ruffie, Gatzemeier, Boyer, Emri, Manegold, Niyikiza, Paoletti (CR3) 2003; 21 Boike, Petru, Sevin, Averette, Chou, Penalver, Donato, Schiano, Hilsenbeck, Perras (CR16) 1990; 38 Latz, Chaudhary, Ghosh, Johnson (CR27) 2006; 57 Usmani, Belvisi, Patel, Crispino, Birrell, Korbonits, Korbonits, Barnes (CR29) 2005; 19 Blasina, Price, Turenne, McGowan (CR7) 1999; 9 Golding, Rosenberg, Khalil, McEwen, Holmes, Neill, Povirk, Valerie (CR11) 2004; 279 Skehan, Storeng, Scudiero, Monks, McMahon, Vistica, Warren, Bokesch, Kenney, Boyd (CR28) 1990; 82 Lu, Errington, Curtin, Lunec, Newell (CR35) 2001; 7 Tsuchiya, Tomita, Yamamoto, Mori, Asada (CR25) 1998; 18 Powell, DeFrank, Connell, Eogan, Preffer, Dombkowski, Tang, Friend (CR32) 1995; 55 Longley, Boyer, Allen, Latif, Ferguson, Maxwell, McDermott, Lynch, Harkin, Johnston (CR36) 2002; 62 Sarkaria, Busby, Tibbetts, Roos, Taya, Karnitz, Abraham (CR5) 1999; 59 Janss, Levow, Bernhard, Muschel, McKenna, Sutton, Phillips (CR14) 1998; 243 Kawahara, Kagiyama, Kanazawa, Tsuchiya, Tomita, Yokogawa, Miyamoto (CR30) 2004; 25 Wang, Boecker, Wang, Wang, Guan, Thompson, Nickoloff, Iliakis (CR10) 2004; 23 Byfield, Murnane, Ward, Calabro-Jones, Lynch, Kulhanian (CR12) 1981; 43 Al Sukhun, Zalupski, Ben Josef, Vaitkevicius, Philip, Soulen, Weaver, Adsay, Heilbrun, Levin, Forman, Shields (CR22) 2003; 26 Hall-Jackson, Cross, Morrice, Smythe (CR6) 1999; 18 Traganos, Kapuscinski, Gong, Ardelt, Darzynkiewicz, Darzynkiewicz (CR19) 1993; 53 Cohen, Schoenfeld, Wolter (CR20) 1980; 64 Tsuchiya, Tomita, Mori, Asada, Morinaga, Kitano, Yamamoto (CR24) 1998; 18 Deplanque, Ceraline, Lapouge, Dufour, Bergerat, Klein-Soyer (CR17) 2004; 314 Dougherty, Kelsen, Kemeny, Magill, Botet, Niedzwiecki (CR21) 1989; 81 Traganos, Kapuscinski, Darzynkiewicz (CR18) 1991; 51 Hayashi, Tsuchiya, Yamamoto, Karita, Shirai, Nishida, Takeuchi, Tomita (CR26) 2005; 25 Russell, Wiens, Demers, Galloway, Plon, Groudine (CR33) 1995; 55 Takahashi, Yanoma, Yamamoto, Rino, Amano, Imada (CR15) 1998; 18 Ahmed, Vaitkevicius, Zalupski, Du, Arlauskas, Gordon, Kellogg, Shields (CR23) 2000; 23 Cortez (CR37) 2003; 278 Zhao, Zhang, Hanscom, Chattopadhyay, Goldman (CR2) 2005; 11 Shih, Chen, Gossett, Gates, MacKellar, Habeck, Shackelford, Mendelsohn, Soose, Patel, Andis, Bewley, Rayl, Moroson, Beardsley, Kohler, Ratnam, Schultz (CR1) 1997; 57 Zhou, Chaturvedi, Spring, Scott, Johanson, Mishra, Mattern, Winkler, Khanna (CR8) 2000; 275 Yao, Akhtar, McKenna, Bedi, Sidransky, Mabry, Ravi, Collector, Jones, Sharkis, Fuchs, Bedi (CR34) 1996; 2 Hanna, Shepherd, Fossella, Pereira, De Marinis, Von Pawel, Gatzemeier, Tsao, Pless, Muller, Lim, Desch, Szondy, Gervais, Shaharyar, Manegold, Paul, Paoletti, Einhorn, Bunn (CR4) 2004; 22 Asaad, Zeng, Guan, Thacker, Iliakis (CR9) 2000; 19 Manfredi, Dong, Liu, Resnick-Silverman, Qiao, Chahinian, Saric, Gibbs, Phillips, Murray, Axten, Nolan, Aaronson (CR31) 2005; 65 11448931 - Clin Cancer Res. 2001 Jul;7(7):2114-23 10485486 - Cancer Res. 1999 Sep 1;59(17):4375-82 15548587 - FASEB J. 2005 Feb;19(2):231-3 12847089 - J Biol Chem. 2003 Sep 26;278(39):37139-45 2065324 - Cancer Res. 1991 Jul 15;51(14):3682-9 14663369 - Am J Clin Oncol. 2003 Dec;26(6):543-9 7712468 - Cancer Res. 1995 Apr 15;55(8):1643-8 8402636 - Cancer Res. 1993 Oct 1;53(19):4613-8 16080466 - Anticancer Res. 2005 May-Jun;25(3c):2399-405 2359136 - J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 16322991 - Cancer Chemother Pharmacol. 2006 Apr;57(4):401-11 7712467 - Cancer Res. 1995 Apr 15;55(8):1639-42 14744854 - J Biol Chem. 2004 Apr 9;279(15):15402-10 11980662 - Cancer Res. 2002 May 1;62(9):2644-9 14737117 - Oncogene. 2004 Jan 22;23(3):824-34 12860938 - J Clin Oncol. 2003 Jul 15;21(14):2636-44 3084068 - Cancer Res. 1986 May;46(5):2463-7 10597277 - Oncogene. 1999 Nov 18;18(48):6707-13 2681796 - J Natl Cancer Inst. 1989 Nov 15;81(22):1735-8 15805256 - Cancer Res. 2005 Apr 1;65(7):2602-9 15117980 - J Clin Oncol. 2004 May 1;22(9):1589-97 10744722 - J Biol Chem. 2000 Apr 7;275(14):10342-8 9854472 - Anticancer Res. 1998 Sep-Oct;18(5B):3651-6 10531013 - Curr Biol. 1999 Oct 7;9(19):1135-8 2121626 - Gynecol Oncol. 1990 Sep;38(3):315-22 9067281 - Cancer Res. 1997 Mar 15;57(6):1116-23 14751246 - Biochem Biophys Res Commun. 2004 Feb 20;314(4):1100-6 7248151 - Br J Cancer. 1981 May;43(5):669-83 9716446 - Exp Cell Res. 1998 Aug 25;243(1):29-38 10955876 - Am J Clin Oncol. 2000 Aug;23(4):420-4 15709201 - Clin Cancer Res. 2005 Feb 1;11(3):1294-301 6991102 - Cancer Treat Rep. 1980 Jan;64(1):151-3 9891499 - Anticancer Res. 1998 Nov-Dec;18(6A):4399-401 11126366 - Oncogene. 2000 Nov 23;19(50):5788-800 8837615 - Nat Med. 1996 Oct;2(10):1140-3 9584049 - Anticancer Res. 1998 Jan-Feb;18(1B):657-66 14872553 - Biopharm Drug Dispos. 2004 Mar;25(2):61-7 CA Hall-Jackson (539_CR6) 1999; 18 SE Golding (539_CR11) 2004; 279 KJ Russell (539_CR33) 1995; 55 X Lu (539_CR35) 2001; 7 H Tsuchiya (539_CR25) 1998; 18 GM Boike (539_CR16) 1990; 38 G Deplanque (539_CR17) 2004; 314 C Shih (539_CR1) 1997; 57 A Blasina (539_CR7) 1999; 9 S Al Sukhun (539_CR22) 2003; 26 H Wang (539_CR10) 2004; 23 DB Longley (539_CR36) 2002; 62 M Hayashi (539_CR26) 2005; 25 M Takahashi (539_CR15) 1998; 18 OS Usmani (539_CR29) 2005; 19 JJ Manfredi (539_CR31) 2005; 65 D Cortez (539_CR37) 2003; 278 NJ Vogelzang (539_CR3) 2003; 21 JE Byfield (539_CR12) 1981; 43 JE Latz (539_CR27) 2006; 57 SN Powell (539_CR32) 1995; 55 S Ahmed (539_CR23) 2000; 23 R Zhao (539_CR2) 2005; 11 BB Zhou (539_CR8) 2000; 275 AJ Janss (539_CR14) 1998; 243 P Skehan (539_CR28) 1990; 82 SL Yao (539_CR34) 1996; 2 F Traganos (539_CR18) 1991; 51 F Traganos (539_CR19) 1993; 53 JB Dougherty (539_CR21) 1989; 81 N Hanna (539_CR4) 2004; 22 HJ Fingert (539_CR13) 1986; 46 MH Cohen (539_CR20) 1980; 64 M Kawahara (539_CR30) 2004; 25 NA Asaad (539_CR9) 2000; 19 JN Sarkaria (539_CR5) 1999; 59 H Tsuchiya (539_CR24) 1998; 18 |
References_xml | – volume: 82 start-page: 1107 year: 1990 end-page: 1112 ident: CR28 article-title: New colorimetric cytotoxicity assay for anticancer-drug screening publication-title: J Natl Cancer Inst doi: 10.1093/jnci/82.13.1107 contributor: fullname: Boyd – volume: 18 start-page: 4399 year: 1998 end-page: 4401 ident: CR15 article-title: Combined effect of CDDP and caffeine against human gastric cell line in vivo publication-title: Anticancer Res contributor: fullname: Imada – volume: 7 start-page: 2114 year: 2001 end-page: 2123 ident: CR35 article-title: The impact of p53 status on cellular sensitivity to antifolate drugs publication-title: Clin Cancer Res contributor: fullname: Newell – volume: 55 start-page: 1639 year: 1995 end-page: 1642 ident: CR33 article-title: Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells publication-title: Cancer Res contributor: fullname: Groudine – volume: 57 start-page: 401 year: 2006 end-page: 411 ident: CR27 article-title: Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-005-0036-1 contributor: fullname: Johnson – volume: 19 start-page: 5788 year: 2000 end-page: 5800 ident: CR9 article-title: Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants publication-title: Oncogene doi: 10.1038/sj.onc.1203953 contributor: fullname: Iliakis – volume: 22 start-page: 1589 year: 2004 end-page: 1597 ident: CR4 article-title: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.163 contributor: fullname: Bunn – volume: 18 start-page: 3651 year: 1998 end-page: 3656 ident: CR25 article-title: Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma publication-title: Anticancer Res contributor: fullname: Asada – volume: 19 start-page: 231 year: 2005 end-page: 233 ident: CR29 article-title: Theobromine inhibits sensory nerve activation and cough publication-title: FASEB J contributor: fullname: Barnes – volume: 275 start-page: 10342 year: 2000 end-page: 10348 ident: CR8 article-title: Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity publication-title: J Biol Chem doi: 10.1074/jbc.275.14.10342 contributor: fullname: Khanna – volume: 21 start-page: 2636 year: 2003 end-page: 2644 ident: CR3 article-title: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.136 contributor: fullname: Paoletti – volume: 46 start-page: 2463 year: 1986 end-page: 2467 ident: CR13 article-title: Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents publication-title: Cancer Res contributor: fullname: Pardee – volume: 18 start-page: 6707 year: 1999 end-page: 6713 ident: CR6 article-title: ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK publication-title: Oncogene doi: 10.1038/sj.onc.1203077 contributor: fullname: Smythe – volume: 57 start-page: 1116 year: 1997 end-page: 1123 ident: CR1 article-title: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes publication-title: Cancer Res contributor: fullname: Schultz – volume: 243 start-page: 29 year: 1998 end-page: 38 ident: CR14 article-title: Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines publication-title: Exp Cell Res doi: 10.1006/excr.1998.4122 contributor: fullname: Phillips – volume: 278 start-page: 37139 year: 2003 end-page: 37145 ident: CR37 article-title: Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases publication-title: J Biol Chem doi: 10.1074/jbc.M307088200 contributor: fullname: Cortez – volume: 18 start-page: 657 year: 1998 end-page: 666 ident: CR24 article-title: Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma publication-title: Anticancer Res contributor: fullname: Yamamoto – volume: 26 start-page: 543 year: 2003 end-page: 549 ident: CR22 article-title: Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study publication-title: Am J Clin Oncol doi: 10.1097/01.coc.0000037143.60502.54 contributor: fullname: Shields – volume: 55 start-page: 1643 year: 1995 end-page: 1648 ident: CR32 article-title: Differential sensitivity of p53(−) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay publication-title: Cancer Res contributor: fullname: Friend – volume: 2 start-page: 1140 year: 1996 end-page: 1143 ident: CR34 article-title: Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase publication-title: Nat Med doi: 10.1038/nm1096-1140 contributor: fullname: Bedi – volume: 23 start-page: 824 year: 2004 end-page: 834 ident: CR10 article-title: Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks publication-title: Oncogene doi: 10.1038/sj.onc.1207168 contributor: fullname: Iliakis – volume: 25 start-page: 61 year: 2004 end-page: 67 ident: CR30 article-title: Rapid determination method of caffeine and application to monitoring of caffeine-assisted chemotherapy publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.384 contributor: fullname: Miyamoto – volume: 59 start-page: 4375 year: 1999 end-page: 4382 ident: CR5 article-title: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine publication-title: Cancer Res contributor: fullname: Abraham – volume: 279 start-page: 15402 year: 2004 end-page: 15410 ident: CR11 article-title: Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells publication-title: J Biol Chem doi: 10.1074/jbc.M314191200 contributor: fullname: Valerie – volume: 81 start-page: 1735 year: 1989 end-page: 1738 ident: CR21 article-title: Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine publication-title: J Natl Cancer Inst doi: 10.1093/jnci/81.22.1735 contributor: fullname: Niedzwiecki – volume: 65 start-page: 2602 year: 2005 end-page: 2609 ident: CR31 article-title: Evidence against a role for SV40 in human mesothelioma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2461 contributor: fullname: Aaronson – volume: 51 start-page: 3682 year: 1991 end-page: 3689 ident: CR18 article-title: Caffeine modulates the effects of DNA-intercalating drugs in vitro: a flow cytometric and spectrophotometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and the doxorubicin analogue AD198 publication-title: Cancer Res contributor: fullname: Darzynkiewicz – volume: 43 start-page: 669 year: 1981 end-page: 683 ident: CR12 article-title: Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents publication-title: Br J Cancer contributor: fullname: Kulhanian – volume: 38 start-page: 315 year: 1990 end-page: 322 ident: CR16 article-title: Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line publication-title: Gynecol Oncol doi: 10.1016/0090-8258(90)90065-S contributor: fullname: Perras – volume: 11 start-page: 1294 year: 2005 end-page: 1301 ident: CR2 article-title: Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis publication-title: Clin Cancer Res contributor: fullname: Goldman – volume: 314 start-page: 1100 year: 2004 end-page: 1106 ident: CR17 article-title: Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.01.006 contributor: fullname: Klein-Soyer – volume: 62 start-page: 2644 year: 2002 end-page: 2649 ident: CR36 article-title: The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates publication-title: Cancer Res contributor: fullname: Johnston – volume: 53 start-page: 4613 year: 1993 end-page: 4618 ident: CR19 article-title: Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells publication-title: Cancer Res contributor: fullname: Darzynkiewicz – volume: 25 start-page: 2399 year: 2005 end-page: 2405 ident: CR26 article-title: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue publication-title: Anticancer Res contributor: fullname: Tomita – volume: 23 start-page: 420 year: 2000 end-page: 424 ident: CR23 article-title: Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study publication-title: Am J Clin Oncol doi: 10.1097/00000421-200008000-00022 contributor: fullname: Shields – volume: 9 start-page: 1135 year: 1999 end-page: 1138 ident: CR7 article-title: Caffeine inhibits the checkpoint kinase ATM publication-title: Curr Biol doi: 10.1016/S0960-9822(99)80486-2 contributor: fullname: McGowan – volume: 64 start-page: 151 year: 1980 end-page: 153 ident: CR20 article-title: Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma publication-title: Cancer Treat Rep contributor: fullname: Wolter – volume: 26 start-page: 543 year: 2003 ident: 539_CR22 publication-title: Am J Clin Oncol doi: 10.1097/01.coc.0000037143.60502.54 contributor: fullname: S Al Sukhun – volume: 25 start-page: 2399 year: 2005 ident: 539_CR26 publication-title: Anticancer Res contributor: fullname: M Hayashi – volume: 243 start-page: 29 year: 1998 ident: 539_CR14 publication-title: Exp Cell Res doi: 10.1006/excr.1998.4122 contributor: fullname: AJ Janss – volume: 25 start-page: 61 year: 2004 ident: 539_CR30 publication-title: Biopharm Drug Dispos doi: 10.1002/bdd.384 contributor: fullname: M Kawahara – volume: 65 start-page: 2602 year: 2005 ident: 539_CR31 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2461 contributor: fullname: JJ Manfredi – volume: 18 start-page: 657 year: 1998 ident: 539_CR24 publication-title: Anticancer Res contributor: fullname: H Tsuchiya – volume: 46 start-page: 2463 year: 1986 ident: 539_CR13 publication-title: Cancer Res contributor: fullname: HJ Fingert – volume: 55 start-page: 1643 year: 1995 ident: 539_CR32 publication-title: Cancer Res contributor: fullname: SN Powell – volume: 19 start-page: 5788 year: 2000 ident: 539_CR9 publication-title: Oncogene doi: 10.1038/sj.onc.1203953 contributor: fullname: NA Asaad – volume: 279 start-page: 15402 year: 2004 ident: 539_CR11 publication-title: J Biol Chem doi: 10.1074/jbc.M314191200 contributor: fullname: SE Golding – volume: 57 start-page: 401 year: 2006 ident: 539_CR27 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-005-0036-1 contributor: fullname: JE Latz – volume: 7 start-page: 2114 year: 2001 ident: 539_CR35 publication-title: Clin Cancer Res contributor: fullname: X Lu – volume: 62 start-page: 2644 year: 2002 ident: 539_CR36 publication-title: Cancer Res contributor: fullname: DB Longley – volume: 51 start-page: 3682 year: 1991 ident: 539_CR18 publication-title: Cancer Res contributor: fullname: F Traganos – volume: 19 start-page: 231 year: 2005 ident: 539_CR29 publication-title: FASEB J doi: 10.1096/fj.04-1990fje contributor: fullname: OS Usmani – volume: 23 start-page: 824 year: 2004 ident: 539_CR10 publication-title: Oncogene doi: 10.1038/sj.onc.1207168 contributor: fullname: H Wang – volume: 278 start-page: 37139 year: 2003 ident: 539_CR37 publication-title: J Biol Chem doi: 10.1074/jbc.M307088200 contributor: fullname: D Cortez – volume: 11 start-page: 1294 year: 2005 ident: 539_CR2 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.1294.11.3 contributor: fullname: R Zhao – volume: 275 start-page: 10342 year: 2000 ident: 539_CR8 publication-title: J Biol Chem doi: 10.1074/jbc.275.14.10342 contributor: fullname: BB Zhou – volume: 82 start-page: 1107 year: 1990 ident: 539_CR28 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/82.13.1107 contributor: fullname: P Skehan – volume: 18 start-page: 3651 year: 1998 ident: 539_CR25 publication-title: Anticancer Res contributor: fullname: H Tsuchiya – volume: 53 start-page: 4613 year: 1993 ident: 539_CR19 publication-title: Cancer Res contributor: fullname: F Traganos – volume: 314 start-page: 1100 year: 2004 ident: 539_CR17 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.01.006 contributor: fullname: G Deplanque – volume: 2 start-page: 1140 year: 1996 ident: 539_CR34 publication-title: Nat Med doi: 10.1038/nm1096-1140 contributor: fullname: SL Yao – volume: 59 start-page: 4375 year: 1999 ident: 539_CR5 publication-title: Cancer Res contributor: fullname: JN Sarkaria – volume: 22 start-page: 1589 year: 2004 ident: 539_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.163 contributor: fullname: N Hanna – volume: 57 start-page: 1116 year: 1997 ident: 539_CR1 publication-title: Cancer Res contributor: fullname: C Shih – volume: 43 start-page: 669 year: 1981 ident: 539_CR12 publication-title: Br J Cancer doi: 10.1038/bjc.1981.98 contributor: fullname: JE Byfield – volume: 81 start-page: 1735 year: 1989 ident: 539_CR21 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/81.22.1735 contributor: fullname: JB Dougherty – volume: 23 start-page: 420 year: 2000 ident: 539_CR23 publication-title: Am J Clin Oncol doi: 10.1097/00000421-200008000-00022 contributor: fullname: S Ahmed – volume: 55 start-page: 1639 year: 1995 ident: 539_CR33 publication-title: Cancer Res contributor: fullname: KJ Russell – volume: 64 start-page: 151 year: 1980 ident: 539_CR20 publication-title: Cancer Treat Rep contributor: fullname: MH Cohen – volume: 38 start-page: 315 year: 1990 ident: 539_CR16 publication-title: Gynecol Oncol doi: 10.1016/0090-8258(90)90065-S contributor: fullname: GM Boike – volume: 9 start-page: 1135 year: 1999 ident: 539_CR7 publication-title: Curr Biol doi: 10.1016/S0960-9822(99)80486-2 contributor: fullname: A Blasina – volume: 21 start-page: 2636 year: 2003 ident: 539_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.136 contributor: fullname: NJ Vogelzang – volume: 18 start-page: 6707 year: 1999 ident: 539_CR6 publication-title: Oncogene doi: 10.1038/sj.onc.1203077 contributor: fullname: CA Hall-Jackson – volume: 18 start-page: 4399 year: 1998 ident: 539_CR15 publication-title: Anticancer Res contributor: fullname: M Takahashi |
SSID | ssj0004133 |
Score | 1.9548651 |
Snippet | Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. Caffeine is known to augment radiation or... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 819 |
SubjectTerms | Antineoplastic agents Ataxia Telangiectasia Mutated Proteins Biological and medical sciences Caffeine - administration & dosage Caffeine - pharmacology Cancer Research Cell Cycle Proteins - drug effects Cell Cycle Proteins - metabolism Cell Line, Tumor Cell Survival - drug effects Checkpoint Kinase 1 DNA-Binding Proteins - drug effects DNA-Binding Proteins - metabolism Dose-Response Relationship, Drug Drug Administration Schedule Folic Acid Antagonists - administration & dosage Folic Acid Antagonists - pharmacology Glutamates - administration & dosage Glutamates - pharmacology Guanine - administration & dosage Guanine - analogs & derivatives Guanine - pharmacology Humans Medical sciences Medicine Medicine & Public Health Mesothelioma - drug therapy Oncology Original Article Pemetrexed Pharmacology. Drug treatments Pharmacology/Toxicology Phosphorylation - drug effects Protein Kinases - drug effects Protein Kinases - metabolism Protein-Serine-Threonine Kinases - drug effects Protein-Serine-Threonine Kinases - metabolism Theobromine - pharmacology Tumor Suppressor Proteins - drug effects Tumor Suppressor Proteins - metabolism |
SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7SDZRC6SN9xE2b6lByaONlbUkr6xhC0qUlJYcE0pOR7RFdkvUusRey--ur8ZNt0kNuBklGmoc00sx8A_BFGY7c2MwPdCp9t0s6lRo7hhAYutDZKLMZZSOf_RpPLsWPK3m1BWH3dJFfD1uPZLVRd7lulRPQr17WJNf--glsS8L7GsD20fffP0_6bMigLiDPhfClGonWl_nQTzZOo-cLUzjC2LqixUMm5_3IyX_cp9WpdPqyzhQsKjBDCka5Hi7LZJiu70M9PmLBr-BFY6Syo1qqXsMW5jvw9Kxxw-_AwXkNeL06ZBd9_lZxyA7YeQ-FvXoDk2NjLboxbEZhQNnNihUUMV9O11iwqj4gm2FBWWA30_nMMPIjMLJ8C1bO2QJnWN7iHWZv4fL05OJ44je1G_xUaFX6KcfROEPljj-OGFrlVN0kMiSDxu2xQthMBxhIFegkVCmPRlJGiRJpIpSyhvN3MMjnOe4CsxxVKKSVUhoxwigy3N0KE-WGc6NT68HXlofxooboiDsw5oqIMX0SEeO1B_sbXO5GhHS11OHYg72W7XGjzkVMsHeaTnIPPnetTg-JKCbH-bKIqQ6AdvaTB-9rEennoqR2t-jQA7UhPF0HQvjebMmnfyqkbx5FMuTag2-tiPRz-u8SPzyq9x48q0NgKBjpIwzK2yV-cnZWmew3ivUXjfogBg priority: 102 providerName: Springer Nature |
Title | Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed |
URI | https://link.springer.com/article/10.1007/s00280-007-0539-z https://www.ncbi.nlm.nih.gov/pubmed/17594092 https://www.proquest.com/docview/213491284 https://search.proquest.com/docview/70319215 https://pubmed.ncbi.nlm.nih.gov/PMC3885239 |
Volume | 61 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED_WBsagjK378rplehh92GpmW1JkPY0spAsbLWE0kD0Z2ZZYoLHT2oUlf_10_iT7ejHGskDS6U53urvfAbwVimqqTOr6MuGulZKWpUaWIAiGzmTqpSbFbOSLy9Fswb4s-bKJzSmasMpWJlaCOs0TvCP_gMhjEoXpx82Ni0Wj0LnaVNA4gEHgM_TSDj5NL-ff-sRIv64lTxlzufBY69b0KhTRIMSkauHafSjd3d7BdLRRhV0jUxe3-Jv2-WcQ5W-e1OqAOn8EDxvNkozrrfAY7unsGO5fNL7zYzid1yjV2zNy1SddFWfklMx7_OrtE5hNlDHa9iFrjN1Jr7ekwDD3crXTBamK-pG1LjB163qVrxXBy3-C6mpBypxs9FqXt_qnTp_C4nx6NZm5TcEFN2FSlG5CtTdKtbDLTLUOjLD8qWIeoBZiBSNjJpW-9rnwZRyIhIYe52EsWBIzIYyi9BkcZnmmXwAxVIuAccM5V8zTYaioNeViYbtTJRPjwLt2taNNjasRdQjKFWkifEXSRDsHhnv06HoEaA_KYOTASUugqOHBIup2jANvulbLPLgoKtP5XREheL-0So8Dz2ti9mMRXFrTN3BA7JG5-wFhufdbstWPCp6bhqG17qUD79sN0Y_pn1N8-d8ZnMCDOk4FI4ZewWF5e6dfW2WojIdwIJbCPsOJP4TB-PP3r9Nhwwb26yIY_wJg5gwC |
link.rule.ids | 230,315,786,790,891,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,41114,41556,42183,42625,43343,43612,43838,52144,52267,74100,74369,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkQAJISiPhkLrA-oBGpGN7XV8QmhFtUC36mEr9RY5yVhdqZtsm1Ri99fjyVPL6xbJseLMy2PPzDcA75XhyI3N_JFOpe-spFOpsWMIgaELnQWZzagaeXY2nl6I75fyss3NKdu0ys4m1oY6K1K6I_9EyGOajOnn1Y1PTaMouNp20LgPDwR3WzUVik-GDA_35aY7shC-VIHogppBjSEaRlRSrXwnhdrfbG1LT1amdBSyTWuLv_mef6ZQ_hZHrbenk2fwtPUr2ZdGEJ7DPcx34eGsjZzvwtF5g1G9PmbzoeSqPGZH7HxAr16_gOnEWItuDltS5k52vWYlJblXiw2WrG7px5ZYUuHW9aJYGkZX_4yc1ZJVBVvhEqtb_InZS7g4-TqfTP223YKfCq0qP-UYjDNUjsgcMbTKaadJZEg-iDOLQthMj3Ak1UgnoUp5FEgZJUqkiVDKGs5fwU5e5LgHzHJUoZBWSmlEgFFkuDvIJcpN50an1oMPHbXjVYOqEff4yTVrYnok1sQbDw62-NHPCOk0qMOxB_sdg-JWA8u4lxcPDvtRpzpEFJNjcVfGBN2vncvjweuGmcNalNTu4Bt6oLbY3L9AoNzbI_niqgbn5lHkzvbag4-dQAxr-ucvvvnvHxzCo-l8dhqffjv7sQ-Pm4wVyh16CzvV7R2-c25RlRzUwv8LJ4QJIw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7aFEKhlDZ9uWkTHUoObUy8lmRZp1K2XbaPhD0kkJuRbYkuZO1N7EB2f31n_Fq2r5tBFsjz0oxn5huAd8pwy43L_ZHOpI9WElUqQoYQGLrQeZC7nLqRT8-i6YX4dikvO0ihqiur7G1iY6jzMqN_5CeEPKbJmJ64ripi9nnycXnt0wApSrR20zTuwwO8FCMS8Hi8qfbAU7STkoXwpQpEn-AMGjzRMKb2auWjRGp_vXVFPVqaCqnl2jEXf_ND_yyn_C2n2lxVkyfwuPMx2adWKJ7CPVvswe5pl0Xfg6NZi1e9Ombnm_ar6pgdsdkGyXr1DKZj45zFPWxBVTz51YpVVPBez9e2Ys14P7awFTVxXc3LhWGUBmDkuFasLtnSLmx9Y-9s_hwuJl_Ox1O_G73gZ0Kr2s-4DaLcKiQ4tzZ0CjXVpDIkfwRNpBAu1yM7kmqk01BlPA6kjFMlslQo5QznL2CnKAv7CpjjVoVCOimlEYGNY8MxqEsVbudGZ86D9z21k2WLsJEMWMoNaxJ6JNYkaw8Otvgx7AgpMtRh5MF-z6Ck08YqGWTHg8NhFdWIiGIKW95WCcH4a3R_PHjZMnNzFiU1BsGhB2qLzcMLBNC9vVLMfzZA3TyOMc7XHnzoBWJzpn9-4uv_fsEh7KLcJz--nn3fh4dt8QqVEb2Bnfrm1r5FD6lODxrZ_wXQEA1h |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caffeine+markedly+sensitizes+human+mesothelioma+cell+lines+to+pemetrexed&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Min%2C+Sang+Hee&rft.au=Goldman%2C+I.+David&rft.au=Zhao%2C+Rongbao&rft.date=2008-04-01&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=61&rft.issue=5&rft.spage=819&rft.epage=827&rft_id=info:doi/10.1007%2Fs00280-007-0539-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00280_007_0539_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |